Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 223-564-1 | CAS number: 3962-66-1
Carcinogenicity
Administrative data
Description of key information
Justification analogues to nandrolone.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
There are no studies on the carcinogenicity of delta-5 -norandrostendion available. However, delta-5 -norandrostendion has a steroidal structure. It has to be taken into account that steroids in general can promote the growth of specific hormone dependent tissues and tumors.
Delta-5 -norandrostendion has a structural similarity to nandrolone and will in vivo be transformed to nandrolone, which is classified according to German legislation (TRGS-905) for anabolic steroids as carc. 2 and is classified with Carc. category 2 according to Regulation (EC) 1272/2008 (CLP).
Based on the information from nandrolone, delta-5 -norandrostendion is classified with category 2 according to Regulation (EC) 1272/2008 (CLP).
Additional information
No carcinogenicity studies are available for delta-5 -norandrostendione. However, delta-5 -norandrostendion has a structural similarity to nandrolone. Only the position of one double bond and a 17-keto group (delta-5 -norandrostendion) instead of a 17-hydroxy group (nandrolone) differs between both substances. But the isomerisation of this double bond from 5,10 -position to 4,5 -position, as well as the transformation to the 17-hydroxy group will easily occur in vivo. Therefore, a close effect relationship between delta-5 -norandrostendion and nandrolone has to be assumed in vivo.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
